CHOP联合抗CCR4抗体莫格利珠单抗治疗老年成人T细胞白血病/淋巴瘤的2期试验
针对老年侵袭性成人T细胞白血病/淋巴瘤(ATL)缺乏标准治疗的问题,这项多中心2期试验评估了每2周CHOP联合莫格利珠单抗(Moga-CHOP-14)方案。48例可评估患者1年无进展生存率为36.2%,完全缓解率64.6%,总缓解率91.7%,未观察到意外毒性。研究显示Moga-CHOP显著改善无进展生存,作者认为其可作为该人群的首选一线治疗。
要点
- 48例可评估患者1年无进展生存率36.2%,1年总生存率66.0%,1年无事件生存率29.9%。
- 完全缓解率64.6%,总缓解率91.7%,未观察到意外毒性。
- CCR4突变和莫格利珠单抗相关皮肤不良事件与更好的总生存相关。
核心结论
- Moga-CHOP显著改善无进展生存,但CHOP的最佳给药间隔尚未确定。
- 作者认为Moga-CHOP目前可作为该患者人群的首选一线治疗。
研究设计与样本
- 多中心2期试验,纳入未治疗的老年ATL患者,年龄≥66岁或56至65岁不适合移植者。
- 方案为6周期Moga-CHOP-14序贯2周期莫格利珠单抗单药治疗,主要终点为1年无进展生存。
- 研究方案经修订允许医生酌定将给药间隔延长至21天。
- 试验注册号jRCTs041180130。
主要发现
- 48例可评估患者1年无进展生存率为36.2%(90%CI 24.9-47.6),中位随访1.6年。
- 1年总生存率为66.0%,1年无事件生存率为29.9%。
- 完全缓解率为64.6%,总缓解率为91.7%。
- 未观察到意外毒性。
- 47例接受≥2周期CHOP的患者中,20例(42.6%)接受CHOP-14,其中12例(25.5%)完成6周期。
临床怎么用
- 作者认为Moga-CHOP目前可作为该患者人群的首选一线治疗。
局限性
- CHOP的最佳给药间隔尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
No standard of care for older patients with aggressive adult T-cell leukemia/lymphoma (ATL) has been established. We evaluated the efficacy of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) every 2 weeks with mogamulizumab (Moga; Moga-CHOP-14) for older patients with untreated ATL. In this multicenter phase 2 trial, patients aged ≥66 years and those aged 56 to 65 years ineligible for transplantation received 6 cycles of Moga-CHOP-14, followed by 2 cycles of Moga monotherapy. The primary end point was 1-year progression-free survival (PFS). Secondary end points were the complete response (CR) rate, overall response rate (ORR), overall survival (OS), 1-year event-free survival (EFS), and safety. We also investigated the impact of CC chemokine receptor 4 (CCR4) mutation and Moga-associated cutaneous adverse events (cAEs) on PFS and OS. The study protocol was amended to allow the dosing interval to be extended to 21 days at the physician's discretion. Among 48 evaluable patients, the 1-year PFS was 36.2% (90% confidence interval, 24.9-47.6), with a median follow-up of 1.6 years. The 1-year OS and EFS were 66.0% and 29.9%, respectively. CR and ORR were 64.6% and 91.7%. No unexpected toxicities were observed. Of 47 patients who received ≥2 cycles of CHOP, 20 (42.6%) received CHOP-14, among whom 12 (25.5%) completed 6 cycles. CCR4 mutation and Moga-associated cAEs were associated with better OS. This study showed that Moga-CHOP significantly improved PFS, although the optimal interval for CHOP remains undetermined. Moga-CHOP is now considered a preferable first-line treatment for this patient population. This trial was registered at https://jrct.mhlw.go.jp/en-top as #jRCTs041180130.
引用
- Yoshimitsu M, Choi I, Kusumoto S, et al. A phase 2 trial of CHOP with anti-CCR4 antibody mogamulizumab for older patients with adult T-cell leukemia/lymphoma. Blood. 2025. PMID: 40373281. doi:10.1182/blood.2024027902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。